Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CUDC 305

Drug Profile

CUDC 305

Alternative Names: CU-0305; CUDC-305; DEBIO 0932; Debio-0932; RGRN-305

Latest Information Update: 06 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Curis
  • Developer Curis; Debiopharm; Regranion
  • Class 2 ring heterocyclic compounds; Antineoplastics; Benzodioxoles; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase I Hidradenitis suppurativa; Plaque psoriasis
  • Phase Unknown Atopic dermatitis; Bullous pemphigoid
  • Discontinued Cancer; Lymphoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 06 Apr 2022 Discontinued - Phase-I for Cancer in USA (PO) before April 2022
  • 06 Apr 2022 Investigation in Atopic dermatitis (unspecified route) before March 2022
  • 06 Apr 2022 Investigation in Bullous pemphigoid (unspecified route) before March 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top